Heart Device Breakthrough Slashes Death Rates, Challenges Stent Era

PARIS, France – May 19, 2026 – The landscape of cardiovascular medicine was rocked today by stunning new data on a novel heart implant that not only props open blocked arteries but allows them to heal and function naturally. At the prestigious EuroPCR 2026 conference, California-based Elixir Medical unveiled four-year results from a major clinical trial showing its DynamX® Bioadaptor slashed cardiovascular death rates by an astonishing 88% compared to a leading drug-eluting stent (DES).

The findings, presented during a late-breaking clinical trial session, suggest a potential paradigm shift away from the decades-long reliance on permanent metal stents. The 445-patient BIOADAPTOR randomized controlled trial (RCT) showed that after four years, patients who received the bioadaptor had a 66% lower rate of target lesion failure (TLF)—a composite measure of cardiac death, heart attack, or re-intervention—than those who received Medtronic's Resolute Onyx™, a widely used drug-eluting stent.

These results, backed by a growing body of evidence from multiple trials involving thousands of patients, position the bioadaptor as a formidable challenger in the multi-billion dollar coronary stent market and offer new hope for improving long-term outcomes for patients with heart disease.

Beyond Caging: A New Philosophy of Restoration

For decades, interventional cardiologists have relied on drug-eluting stents to treat coronary artery disease. These small, mesh-like tubes are highly effective at opening a blockage and restoring blood flow. However, they come with a long-term trade-off: they permanently cage the artery.

“Interventional cardiologists typically use a drug-eluting stent (DES) during percutaneous coronary intervention (PCI) to open the heart blockage and keep the artery open. These interlocked mesh-like tubes, however, permanently cage the artery, limiting its function and contributing to an annual 2-3% increase in adverse clinical events over time,” explained Professor Stefan Verheye, an interventional cardiologist at ZNA Cardiovascular Center in Antwerp, Belgium, and a leading investigator for the trial.

The DynamX® Bioadaptor is designed to overcome this fundamental limitation. It represents a new class of implant that works in distinct phases. Initially, it acts like a stent, providing a rigid scaffold to establish maximum blood flow. But its true innovation is what happens next. Over the first six months, a bioresorbable polymer coating dissolves, allowing the device’s unique helical strands to unlock and separate. This “uncaging” process transforms the rigid implant into a flexible support system that moves with the artery, allowing it to regain its natural pulsatility, compliance, and ability to adapt to the body’s changing need for blood flow.

“The bioadaptor is a new type of unlocking, adaptive implant designed to keep the artery open while restoring normal vessel function, its compliance and pulsatility,” Professor Verheye added.

A Plateau of Safety and Unprecedented Outcomes

The clinical impact of this functional restoration, as detailed in the four-year data, is profound. The headline 88% reduction in cardiovascular death (0.5% for DynamX® vs. 3.7% for the DES) was statistically significant and a finding that captured the attention of the cardiology community.

“The significant finding in reducing cardiovascular mortality marks a major achievement in how we treat cardiovascular disease and improve patient outcomes,” remarked Shigeru Saito, M.D., the trial's principal investigator and director at Shonan Kamakura General Hospital in Japan.

Perhaps even more telling is the long-term trajectory of patient outcomes. While adverse event rates for DES patients continue to climb steadily year after year, the DynamX® arm of the study showed a remarkable stabilization. Between the three- and four-year follow-up points, there were no new cardiovascular deaths or target lesion failures recorded among the bioadaptor patients. This suggests that by restoring natural vessel function, the device may mitigate the long-term risks associated with a permanent implant.

The benefits were particularly pronounced in the left anterior descending (LAD) artery, the critical vessel responsible for supplying roughly half of the heart's blood. In this crucial location, the rate of target lesion failure was dramatically lower with DynamX® compared to the DES (2.7% versus 10.6%). This may reflect an amplified benefit of restoring vessel motion and pulsatility in such a hemodynamically vital artery.

Challenging a Multi-Billion Dollar Market

The implications of these findings extend far beyond the clinic, sending ripples through the estimated $8.6 billion global coronary stent market. This sector is dominated by medical device giants like Medtronic, Boston Scientific, and Abbott, whose drug-eluting stents are the current standard of care. Elixir Medical, a privately held company, is now positioned as a disruptive force with a technology that addresses the known shortcomings of its competitors' flagship products.

The data's consistency across multiple trials strengthens Elixir's case. The results from the BIOADAPTOR RCT are mirrored by findings from the even larger 2,400-patient INIFINITY-SWEDEHEART trial, which also showed a divergence in event rates favoring DynamX® over time.

“The four-year BIOADAPTOR-RCT data presented today, and the results from the 2,400 patient INIFINITY-SWEDEHEART RCT have shown consistently across multiple randomized clinical trials significantly lower, plateauing clinical events with DynamX® bioadaptor compared to DES treatment,” said Motasim Sirhan, CEO of Elixir Medical.

While the path to widespread adoption is complex, Elixir has key advantages. The DynamX® system is already CE-marked, permitting its use in Europe. In the United States, it has been granted Breakthrough Device Designation by the FDA, a program designed to expedite the review of technologies that could provide more effective treatment for life-threatening diseases. However, challenges remain. Convincing hospitals and physicians to shift from decades of established practice will require significant educational efforts, and navigating reimbursement and cost-effectiveness arguments in global healthcare systems will be crucial. Nonetheless, the promise of not just treating a blockage, but restoring the artery to a more natural state, represents a powerful value proposition that could fundamentally reshape the future of cardiovascular intervention.